Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066996
Filing Date
2025-05-08
Accepted
2025-05-08 16:15:42
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vtyx-20250331.htm   iXBRL 10-Q 2804622
2 EX-31.1 vtyx-ex31_1.htm EX-31.1 19713
3 EX-31.2 vtyx-ex31_2.htm EX-31.2 19728
4 EX-32.1 vtyx-ex32_1.htm EX-32.1 11785
5 EX-32.2 vtyx-ex32_2.htm EX-32.2 11795
  Complete submission text file 0000950170-25-066996.txt   10536052

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vtyx-20250331.xsd EX-101.SCH 1157638
69 EXTRACTED XBRL INSTANCE DOCUMENT vtyx-20250331_htm.xml XML 2134418
Mailing Address 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130
Business Address 12790 EL CAMINO REAL, SUITE 200 SAN DIEGO CA 92130 (858) 945-2393
Ventyx Biosciences, Inc. (Filer) CIK: 0001851194 (see all company filings)

EIN.: 832996852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40928 | Film No.: 25926330
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)